Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Summary

This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by slowing or stopping a certain type of receptor called vascular endothelial growth factor receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine tumors by blocking the growth of new blood vessels necessary for tumor growth.

Timeline

Start

2015-05-15

Primary completion

2019-09-01

Completion

2022-08-31

Drugs

Indications